Treatment and Improvement of Healing after Surgical Intervention
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lingzhi, Z.; Meirong, L.; Xiaobing, F. Biological Approaches for Hypertrophic Scars. Int. Wound J. 2020, 17, 405–418. [Google Scholar] [CrossRef] [PubMed]
- Dunphy, J.E. Wound Healing. Surg. Clin. N. Am. 1978, 58, 907–916. [Google Scholar] [CrossRef] [PubMed]
- Ferguson, E.L.; Roberts, J.L.; Moseley, R.; Griffiths, P.C.; Thomas, D.W. Evaluation of the Physical and Biological Properties of Hyaluronan and Hyaluronan Fragments. Int. J. Pharm. 2011, 420, 84–92. [Google Scholar] [CrossRef]
- Son, D.; Harijan, A. Overview of Surgical Scar Prevention and Management. J. Korean Med. Sci. 2014, 29, 751–757. [Google Scholar] [CrossRef] [Green Version]
- Almine, J.F.; Wise, S.G.; Weiss, A.S. Elastin Signaling in Wound Repair. Birth Defects Res. Part C Embryo Today 2012, 96, 248–257. [Google Scholar] [CrossRef]
- Monslow, J.; Sato, N.; MacK, J.A.; Maytin, E.V. Wounding-Induced Synthesis of Hyaluronic Acid in Organotypic Epidermal Cultures Requires the Release of Heparin-Binding EGF and Activation of the EGFR. J. Investig. Dermatol. 2009, 129, 2046–2058. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Slemp, A.E.; Kirschner, R.E. Keloids and Scars: A Review of Keloids and Scars, Their Pathogenesis, Risk Factors, and Management. Curr. Opin. Pediatr. 2006, 18, 396–402. [Google Scholar] [CrossRef]
- Freedman, B.R.; Hwang, C.; Talbot, S.; Hibler, B.; Matoori, S.; Mooney, D.J. Breakthrough Treatments for Accelerated Wound Healing. Sci. Adv. 2023, 9, eade7007. [Google Scholar] [CrossRef]
- Watson, D.; Reuther, M. Scar Revision Techniquespearls and Pitfalls. Facial Plast. Surg. 2012, 28, 487–491. [Google Scholar] [CrossRef]
- Gantwerker, E.A.; Hom, D.B. Skin: Histology and Physiology of Wound Healing. Facial Plast. Surg. Clin. N. Am. 2011, 19, 441–453. [Google Scholar] [CrossRef]
- David Chang, C.W.; Russell Ries, W. Nonoperative Techniques for Scar Management and Revision. Facial Plast. Surg. 2001, 17, 283–287. [Google Scholar] [CrossRef] [PubMed]
- González, N.; Goldberg, D.J. Update on the Treatment of Scars. J. Drugs Dermatol. 2019, 18, 550–555. [Google Scholar] [PubMed]
- Ogawa, R. The Most Current Algorithms for the Treatment and Prevention of Hypertrophic Scars and Keloids: A 2020 Update of the Algorithms Published 10 Years Ago. Plast. Reconstr. Surg. 2022, 149, 79E–94E. [Google Scholar] [CrossRef] [PubMed]
- Ziegler, U.E. Internationale Klinische Empfehlungen Zur Narbenbehandlung. Zentralbl. Chir. 2004, 129, 296–306. [Google Scholar] [CrossRef] [PubMed]
- Riccio, M.; Marchesini, A.; Senesi, L.; Skrami, E.; Gesuita, R.; De Francesco, F. Managing Pathologic Scars by Injecting Auto-Cross-Linked Hyaluronic Acid: A Preliminary Prospective Clinical Study. Aesthet. Plast. Surg. 2019, 43, 480–489. [Google Scholar] [CrossRef] [PubMed]
- Gupta, S.; Garg, S.; Dahiya, N. Surgical Scar Revision: An Overview. J. Cutan. Aesthet. Surg. 2014, 7, 3. [Google Scholar] [CrossRef]
- Kerwin, L.Y.; El Tal, A.K.; Stiff, M.A.; Fakhouri, T.M. Scar Prevention and Remodeling: A Review of the Medical, Surgical, Topical and Light Treatment Approaches. Int. J. Dermatol. 2014, 53, 922–936. [Google Scholar] [CrossRef]
- Lee Peng, G.; Kerolus, J.L. Management of Surgical Scars. Facial Plast. Surg. Clin. N. Am. 2019, 27, 513–517. [Google Scholar] [CrossRef]
- Urrútia, G.; Bonfill, X. PRISMA Declaration: A Proposal to Improve the Publication of Systematic Reviews and Meta-Analyses. Med. Clin. 2010, 135, 507–511. [Google Scholar] [CrossRef]
- Sackett, D.L.; Rosenberg, W.M.C.; Gray, J.A.M.; Haynes, R.B.; Richardson, W.S. Evidence Based Medicine: What It Is and What It Isn’t. 1996. Clin. Orthop. Relat. Res. 2007, 455, 3–5. [Google Scholar]
- Sherrington, C.; Herbert, R.D.; Maher, C.G.; Moseley, A.M. PEDro. A Database of Randomized Trials and Systematic Reviews in Physiotherapy. Man. Ther. 2000, 5, 223–226. [Google Scholar] [CrossRef] [PubMed]
- Abedini, R.; Mehdizade Rayeni, N.; Haddady Abianeh, S.; Rahmati, J.; Teymourpour, A.; Nasimi, M. Botulinum Toxin Type A Injection for Mammoplasty and Abdominoplasty Scar Management: A Split-Scar Double-Blinded Randomized Controlled Study. Aesthet. Plast. Surg. 2020, 44, 2270–2276. [Google Scholar] [CrossRef]
- Chen, Z.; Jin, Y.; Zou, Y.; Qiu, Y.; Hu, L.; Chang, L.; Chen, H.; Lin, X. Scar Prevention with Prolonged Use of Tissue Adhesive Zipper Immediately after Facial Surgery: A Randomized Controlled Trial. Aesthet. Surg. J. 2022, 42, NP265–NP272. [Google Scholar] [CrossRef]
- Chen, Z.; Chen, Z.; Pang, R.; Wei, Z.; Zhang, H.; Liu, W.; Li, G. The Effect of Botulinum Toxin Injection Dose on the Appearance of Surgical Scar. Sci. Rep. 2021, 11, 13670. [Google Scholar] [CrossRef] [PubMed]
- Chung, J.H.; Kim, D.S.; Cheon, J.H.; Yoon, J.M.; Baek, S.K.; Jung, K.Y.; Yoon, E.S.; Park, S.H. Current Protocol for Aesthetic Scar Management in Thyroid Surgery. Laryngoscope 2021, 131, E2188–E2195. [Google Scholar] [CrossRef] [PubMed]
- Dolynchuk, K.N.; Tredget, E.E. A Preliminary Report of the Biochemical and Clinical Effects of 1,4-Diaminobutane on Prevention of Human Hypertrophic Scars. Plast. Reconstr. Surg. 2020, 145, 76e–84e. [Google Scholar] [CrossRef] [PubMed]
- Huang, R.L.; Ho, C.K.; Tremp, M.; Xie, Y.; Li, Q.; Zan, T. Early Postoperative Application of Botulinum Toxin Type A Prevents Hypertrophic Scarring after Epicanthoplasty: A Split-Face, Double-Blind, Randomized Trial. Plast. Reconstr. Surg. 2019, 144, 835–844. [Google Scholar] [CrossRef]
- Ilori, O.S.; Oladele, A.O.; Ilori, O.R.; Onilede, D.A. Efficacy of Microporous Tape in the Prevention of Abnormal Post-Surgical Scars among a Black Population. J. Ayub Med. Coll. Abbottabad 2022, 34, 223–229. [Google Scholar] [CrossRef] [PubMed]
- Jensen, J.; Gentzkow, G.; Berman, G.; Senne, L.; Jewell, M.; Connall, T.P.; Miller, S.R.; Galiano, R.D.; Young, L. Anti-CTGF Oligonucleotide Reduces Severity of Postsurgical Hypertrophic Scars in a Randomized, Double-Blind, within-Subject, Placebo-Controlled Study. Plast. Reconstr. Surg. 2018, 142, 192E–201E. [Google Scholar] [CrossRef]
- Karmisholt, K.E.; Banzhaf, C.A.; Glud, M.; Yeung, K.; Paasch, U.; Nast, A.; Haedersdal, M. Laser Treatments in Early Wound Healing Improve Scar Appearance: A Randomized Split-Wound Trial with Nonablative Fractional Laser Exposures vs. Untreated Controls. Br. J. Dermatol. 2018, 179, 1307–1314. [Google Scholar] [CrossRef] [Green Version]
- Kong, X.; Yang, M.; Cao, Z.; Chen, J.; Chai, W.; Wang, Y. Tissue Adhesive for Wound Closure in Enhanced-Recovery Total Hip Arthroplasty: A Prospective, Randomized and Controlled Study. BMC Musculoskelet. Disord. 2020, 21, 178. [Google Scholar] [CrossRef] [Green Version]
- Lin, M.J.; Dubin, D.P.; Torbeck, R.L.; Bernstein, D.M.; Nabatian, A.; Dolan, C.K.; Bacigalupi, R.; Zade, J.; Zheng, Z.; Desman, G.; et al. Early Fractional Ablative Laser for Skin Cancer Excision Scars: A Randomized Split-Scar Study. Dermatol. Surg. 2023, 49, 338–342. [Google Scholar] [CrossRef]
- Musham, A.; Samuel, E.M.K.; Sahoo, A.K.; Elamurugan, T.P.; Manwar, A.S. Comparison of Tissue Adhesive Glue with Subcuticular Absorbable Suture for Skin Closure Following Thyroid Surgery A Single-Blinded Randomised Controlled Trial. Sultan Qaboos Univ. Med. J. 2023, 23, 42–47. [Google Scholar] [CrossRef] [PubMed]
- Pangkanon, W.; Yenbutra, P.; Kamanamool, N.; Tannirandorn, A.; Udompataikul, M. A Comparison of the Efficacy of Silicone Gel Containing Onion Extract and Aloe Vera to Silicone Gel Sheets to Prevent Postoperative Hypertrophic Scars and Keloids. J. Cosmet. Dermatol. 2021, 20, 1146–1153. [Google Scholar] [CrossRef]
- Phillips, T.J.; Fung, E.; Rigby, M.H.; Burke, E.; Hart, R.D.; Trites, J.R.B.; Gassner, H.G.; Taylor, S.M. The Use of Botulinum Toxin Type A in the Healing of Thyroidectomy Wounds. Plast. Reconstr. Surg. 2019, 143, 375e–381e. [Google Scholar] [CrossRef] [PubMed]
- Ramos, R.M.; Burland, M.; Silva, J.B.; Burman, L.M.; Gelain, M.S.; Debom, L.M.; Bec, J.M.; Alirezai, M.; Uebel, C.O.; Valmier, J.; et al. Photobiomodulation Improved the First Stages of Wound Healing Process After Abdominoplasty: An Experimental, Double-Blinded, Non-Randomized Clinical Trial. Aesthet. Plast. Surg. 2019, 43, 147–154. [Google Scholar] [CrossRef]
- Safra, T.; Shehadeh, W.; Koren, A.; Salameh, F.; Friedman, O.; Sprecher, E.; Artzi, O. Early Intervention with Pulse Dye and CO2 Ablative Fractional Lasers to Improve Cutaneous Scarring Post-Lumpectomy: A Randomized Controlled Trial on the Impact of Intervention on Final Cosmesis. Lasers Med. Sci. 2019, 34, 1881–1887. [Google Scholar] [CrossRef]
- Surakunprapha, P.; Winaikosol, K.; Chowchuen, B.; Jenwithaesuk, K.; Jenwitheesuk, K. Adding Herbal Extracts to Silicone Gel on Post-Sternotomy Scar: A Prospective Randomised Double-Blind Study. J. Wound Care 2020, 29, S36–S42. [Google Scholar] [CrossRef] [PubMed]
- Suwannaphisit, S.; Aonsong, W.; Suwanno, P.; Yuenyongviwat, V. Comparing the Running Subcuticular Technique versus the Donati Technique in Open Carpal Tunnel Release: A Randomized Controlled Trial. J. Orthop. Surg. Res. 2021, 16, 565. [Google Scholar] [CrossRef] [PubMed]
- Timmermans, F.W.; Mokken, S.E.; Smit, J.M.; Bouman, M.B.; van de Grift, T.C.; Mullender, M.G.; Middelkoop, E. The Impact of Incisional Negative Pressure Wound Therapy on Scar Quality and Patient-Reported Outcomes: A within-Patient-Controlled, Randomised Trial. Wound Repair Regen. 2022, 30, 210–221. [Google Scholar] [CrossRef]
- Zhang, S.; Nabi, O.; Jiang, X. New Strategy of Modulating Incision Tension: A Wound Tension Offloading Device Applied before Surgery. Dermatol. Ther. 2021, 34, e14797. [Google Scholar] [CrossRef] [PubMed]
- Zoumalan, C.I.; Tadayon, S.C.; Roostaeian, J.; Rossi, A.M.; Gabriel, A. Safety and Efficacy of a Scar Cream Consisting of Highly Selective Growth Factors within a Silicone Cream Matrix: A Double-Blinded, Randomized, Multicenter Study. Aesthet. Surg. J. 2019, 39, 319–330. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kemaloğlu, C.A.; Özyazgan, İ.; Gönen, Z.B. Immediate Fat and Nanofat-Enriched Fat Grafting in Breast Reduction for Scar Management. J. Plast. Surg. Hand Surg. 2021, 55, 173–180. [Google Scholar] [CrossRef]
- Yuan, X.; Shen, J.; Chen, L.; Wang, L.; Yan, Q.; Zhang, J. Onion Extract Gel Is Not Better than Other Topical Treatments in Scar Management: A Meta-Analysis from Randomised Controlled Trails. Int. Wound J. 2021, 18, 396–409. [Google Scholar] [CrossRef]
- Januszyk, M.; Wong, V.W.; Bhatt, K.A.; Vial, I.N.; Paterno, J.; Longaker, M.T.; Gurtner, G.C. Mechanical Offloading of Incisional Wounds Is Associated with Transcriptional Downregulation of Inflammatory Pathways in a Large Animal Model. Organogenesis 2014, 10, 186–193. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wong, V.W.; Beasley, B.; Zepeda, J.; Dauskardt, R.H.; Yock, P.G.; Longaker, M.T.; Gurtner, G.C. A Mechanomodulatory Device to Minimize Incisional Scar Formation. Adv. Wound Care 2013, 2, 185–194. [Google Scholar] [CrossRef] [Green Version]
- Wang, D.; Ding, J.; Jiang, Y.; Liu, Y.; Chen, B. Continuous Tension Reduction Technique in Facial Scar Management: A Comparison of W-Plasty and Straight-Line Closure on Aesthetic Effects in Asian Patients. Int. Wound J. 2022, 19, 1064–1070. [Google Scholar] [CrossRef] [PubMed]
- Scalise, A.; Calamita, R.; Tartaglione, C.; Pierangeli, M.; Bolletta, E.; Gioacchini, M.; Gesuita, R.; Di Benedetto, G. Improving Wound Healing and Preventing Surgical Site Complications of Closed Surgical Incisions: A Possible Role of Incisional Negative Pressure Wound Therapy. A Systematic Review of the Literature. Int. Wound J. 2016, 13, 1260–1281. [Google Scholar] [CrossRef] [PubMed]
- Armour, A.; Scott, P.G.; Tredget, E.E. Cellular and Molecular Pathology of HTS: Basis for Treatment. Wound Repair Regen. 2007, 15, S6–S17. [Google Scholar] [CrossRef]
- Klotz, T. The Effect of Moisturisers on Scars: A Systematic Review. Ph.D. Thesis, University of Adelaide, Adelaide, Australia, 2018. [Google Scholar]
- Cheng, J.W.; Cheng, S.W.; Wei, R.L.; Lu, G.C. Anti-Vascular Endothelial Growth Factor for Control of Wound Healing in Glaucoma Surgery. Cochrane Database Syst. Rev. 2016, 2016, CD009782. [Google Scholar] [CrossRef]
- Zhang, Y.; Wang, T.; He, J.; Dong, J. Growth Factor Therapy in Patients with Partial-Thickness Burns: A Systematic Review and Meta-Analysis. Int. Wound J. 2016, 13, 354–366. [Google Scholar] [CrossRef] [PubMed]
- Santamato, A.; Cinone, N.; Panza, F.; Letizia, S.; Santoro, L.; Lozupone, M.; Daniele, A.; Picelli, A.; Baricich, A.; Intiso, D.; et al. Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke. Drugs 2019, 79, 143–160. [Google Scholar] [CrossRef] [PubMed]
- Picelli, A.; Santamato, A.; Chemello, E.; Cinone, N.; Cisari, C.; Gandolfi, M.; Ranieri, M.; Smania, N.; Baricich, A. Adjuvant Treatments Associated with Botulinum Toxin Injection for Managing Spasticity: An Overview of the Literature. Ann. Phys. Rehabil. Med. 2019, 62, 291–296. [Google Scholar] [CrossRef]
- Park, J.H.; Park, H.J. Botulinum Toxin for the Treatment of Neuropathic Pain. Toxins 2017, 9, 260. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jeong, H.S.; Lee, B.H.; Sung, H.M.; Park, S.Y.; Ahn, D.K.; Jung, M.S.; Suh, I.S. Effect of Botulinum Toxin Type A on Differentiation of Fibroblasts Derived from Scar Tissue. Plast. Reconstr. Surg. 2015, 136, 171e–178e. [Google Scholar] [CrossRef] [PubMed]
- Scala, J.; Vojvodic, A.; Vojvodic, P.; Vlaskovic-Jovicevic, T.; Peric-Hajzler, Z.; Matovic, D.; Dimitrijevic, S.; Vojvodic, J.; Sijan, G.; Stepic, N.; et al. Botulin Toxin Use in Scars/Keloids Treatment. Open Access Maced. J. Med. Sci. 2019, 7, 2979–2981. [Google Scholar] [CrossRef] [Green Version]
- Arias-Rodríguez, C. Toxina Botulínica: Usos Novedosos y Su Evidencia Botulinum Toxin: Novel Uses and Evidence. Dermatol. Cosmét. Med. Quir. 2022, 20, 448–452. [Google Scholar]
- Ashraf, I.; Butt, E.; Veitch, D.; Wernham, A. Dermatological Surgery: An Update on Suture Materials and Techniques: Part 1. Clin. Exp. Dermatol. 2021, 46, 1400–1410. [Google Scholar] [CrossRef]
- Butt, E.; Ashraf, I.; Veitch, D.; Wernham, A. Dermatological Surgery: An Update on Suture Materials and Techniques: Part 2. Clin. Exp. Dermatol. 2021, 46, 1411–1419. [Google Scholar] [CrossRef]
- Byrne, M.; Aly, A. The Surgical Suture. Aesthet. Surg. J. 2019, 39, S67–S72. [Google Scholar] [CrossRef] [Green Version]
- Chowdhury, B.; Kassir, M.; Salas-Alanis, J.; Nistico, S.; Galadari, H.; Fritz, K.; Salavastru, C.; Blicharz, L.; Goldust, M. Laser in Surgical Scar Clearance: An Update Review. J. Cosmet. Dermatol. 2021, 20, 3808–3811. [Google Scholar] [CrossRef] [PubMed]
Population | Surgical Procedures Population |
Intervention | Recent approaches of cicatrization process |
Outcomes | Quality of scars |
Research question | What are the current approaches to improve the quality of scars in surgical procedures population? |
Database | Search Strategy |
---|---|
PubMed | ((“cicatrix” [MeSH Terms] OR “cicatrix” [All Fields] OR “cicatrization” [All Fields] OR “cicatrize” [All Fields] OR “cicatrized” [All Fields] OR “cicatrizing” [All Fields]) AND “Cicatrix, Hypertrophic” [Mesh] AND (prevention) AND (treatment) AND (surgery [Title/Abstract]) OR (surgical scar [Title/Abstract]) NOT (burn* [Title/Abstract])) |
Web of Science | ((((AB=(cicatrization)) OR AB=(“hypertrophic cicatrix” OR “surgical scar”)) AND AB=(treatment OR therapy)) AND AB=(surgery)) NOT ALL=(conjunctivitis OR burn) |
Scopus | TITLE-ABS-KEY (cicatrization) AND TITLE-ABS-KEY (treatment OR therapy) AND TITLE-ABS-KEY (surgery) OR TITLE-ABS-KEY (surgical AND scar) |
ScienceDirect | (cicatrization) OR (hypertrophic cicatrix AND prevention) AND (treatment) AND (“surgery” OR “surgical scar” OR) NOT (conjunctivitis OR burn) |
Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | Score | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Abedini et al., 2020 [22] | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 11 |
Chen Z et al., 2022 [23] | Y | Y | Y | Y | N | N | N | Y | Y | Y | Y | 8 |
Chen et al., 2021 [24] | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | N | 9 |
Chung et al., 2021 [25] | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | 10 |
Dolynchuk et al., 2020 [26] | Y | Y | Y | N | Y | Y | Y | N | Y | Y | Y | 9 |
Huang et al., 2019 [27] | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | 10 |
Ilori et al., 2022 [28] | Y | Y | Y | Y | N | N | N | Y | Y | Y | Y | 8 |
Jensen et al., 2018 [29] | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 11 |
Karmisholt et al., 2018 [30] | Y | Y | Y | Y | N | N | Y | Y | Y | Y | Y | 9 |
Kong et al., 2020 [31] | Y | Y | Y | Y | N | Y | N | Y | Y | Y | Y | 9 |
Lin et al., 2023 [32] | Y | Y | N | Y | N | N | Y | Y | Y | Y | Y | 8 |
Musham et al., 2023 [33] | Y | Y | Y | Y | N | N | Y | Y | Y | Y | Y | 9 |
Pangkanon et al., 2021 [34] | Y | Y | Y | Y | N | N | Y | Y | Y | Y | Y | 9 |
Phillips et al., 2018 [35] | Y | Y | Y | N | Y | N | Y | N | Y | Y | Y | 8 |
Ramos et al., 2019 [36] | Y | N | Y | Y | Y | N | Y | Y | Y | Y | Y | 9 |
Safra et al., 2019 [37] | Y | N | Y | Y | N | N | Y | Y | Y | Y | Y | 8 |
Surakunprapha et al., 2020 [38] | Y | Y | Y | Y | Y | N | Y | Y | Y | N | Y | 9 |
Suwannaphisit et al., 2021 [39] | Y | Y | Y | N | Y | N | Y | Y | Y | Y | Y | 9 |
Timmermans et al., 2022 [40] | Y | Y | Y | Y | N | N | Y | Y | Y | Y | Y | 9 |
Zhang et al., 2021 [41] | Y | Y | Y | Y | N | N | Y | Y | Y | Y | N | 8 |
Zoumalan et al., 2019 [42] | Y | Y | Y | N | Y | N | Y | N | Y | Y | Y | 8 |
Study/Author | Typology/Main Objective | Participants | Interventions | Evaluation | Main Findings | PEDro |
---|---|---|---|---|---|---|
Abedini et al., 2020 [22] | Randomized, split-scar, double- blinded, prospective, controlled trial. To investigate the role of botulinum toxin on the prevention of scar formation in comparison with control in cosmetic plastic surgeries including mammoplasty and abdominoplasty. | n = 19 Patients of mammoplasty and abdominoplasty. 26–54 years old. Sex (f/m): 19/0 | Botulinum toxin (EG) or saline solution (CG) on each side of scar. | mSBSES Assessments at 3 and 6 months | Significant improvements in EG compared to CG at 3 and 6 months (p < 0.001 each). Also, in the subset analysis, there were significant differences between groups in width, height, color, and scar visibility at months 3 and 6. In EG, scores of mSBSES, height, visibility, and redness (p < 0.001; p = 0.002; p = 0.002; p = 0.008) increased significantly from month 3 to 6, but the scar width did not change significantly (p = 0.051). In CG scores of mSBSES, height, and redness (p = 0.0015; p = 0.038; p = 0.019) improved significantly over time, but scar width and visibility (p = 0.34; p = 0.24) did not change significantly. | 11 |
Chen et al., 2022 [23] | Randomized, controlled, prospective, rated blinded trial. To determinate efficacy and safety of tissue adhesive zippers in post-surgical scar prevention among patients undergoing surgical excision of the face. | n = 53 Patients with surgical excision on the face. <14 years old. Sex (f/m): 30/23 | EG participants used a tissue adhesive zipper for three months. CG no intervention. | Scar Width. POSAS Assessments at 1, 3, 6, 12 months. | In EG group the scar width was significantly smaller than CG (p = 0.0025) at 12 months. EG and CG differed significantly in POSAS scores for Scar irregularity (p = 0.0145). No differences between groups in the other scores and observer score. | 8 |
Chen et al., 2021 [24] | Randomized, prospective, double-blind, split-scar trial. To investigate the effect of different doses of botulinum toxin administered early after surgery on scar improvement through a split-scar experiment. | n = 22 Tumor resection (tumor did not invade the muscle) 18–52 years old. Sex (f/m): 9/11 | High and low doses of botulinum toxin into each half of the surgical wound closure. | mSBSES. VAS. Assessment at 6 months | The high-dose sides had significantly better mSBSES score compared with low-dose in terms of width (p < 0.01), incision visibility line (p < 0.01). No significant differences between groups in height and color. High-dose sides had significantly higher VAS scores than low-dose sides (p < 0.01). | 9 |
Chung et al. 2021 [25] | Randomized, blinded, prospective trial. To compare the scar quality when different protocols were applied, and eventually aim to find the optimal scar management protocol | N = 126 Patients undergoing thyroidectomy. >18 years old Sex (f/m): 105/21 | Tissue adhesive (group A), or subcuticular suturing and early NAFL (group B), or skin closure with tissue adhesive and early NAFL (group C) | POSAS. Assessment at 6 months. | No significant differences between groups at baseline. At 6 months, B group showed a narrower width scar, with no differences between A and C (p > 0.017). According to the patients, groups B and C showed significantly higher satisfaction in all sub-scales than A except for the pigmentation. According to physicians, B showed better thickness, relief, pliability, surface area, and overall cosmesis (p < 0.017) with no differences between A and C (p > 0.017). | 10 |
Dolynchuk et al., 2020 [26] | Randomized, prospective, double-blind trial. To analyze the biochemical and clinical effects of 1,4-Diaminobutane (DAB)on prevention of human hypertrophic scars. | Total n = 78 patients of breast reduction. Biochemical evaluation n = 30 Clinical evaluation n = 48 5–53 years old. Sex (f/m): 50/10 | Topical 1,4-DAB or control treatment on each side (EG or CG respectively). | Biochemical: Analytical assessment (biopsy) At 2 months Clinical: Durometer test POSAS At 6 and 12 weeks | The biopsies registered more 1,4DAB in treated scars than control group (p < 0.05). Durometer test was significantly better (p < 0.05) in EG. POSAS score was significantly better in EG than CG (p < 0.05) | 9 |
Huang et al., 2019 [27] | Randomized, prospective, double blind, split-face trial. To investigate the safety and efficacy of early botulinum toxin A injection in preventing hypertrophic scarring in the medial cantal area after epicanthoplasty. | n = 43 Patients of epicanthoplasty. 18–45 years old. Sex (f/m): 43/0 | Botulinum toxin A (EG) or saline treatment (placebo side) into each side of surgery. | VSS VAS. Patient Satisfaction Assessment al 1, 3, 6 months | 13 patients were lost to follow-up. The botulinum toxin A side had significantly better scores at VSS 1 month (p = 0.034), 3 months (p < 0.001), and 6 months (p < 0.001) after administration. The same was found at VAS (p = 0.017; p < 0.001; p = 0.032 respectively). Patient satisfaction was better with botulinum toxin A (p < 0.001) | 10 |
Ilori et al., 2022 [28] | Randomized, controlled, prospective trial. To determinate the efficacy of microporous tape in the prevention of abnormal post-surgical scars. | n = 72 patients with 92 scars EG n = 36 CG n = 36 Benign tumors excision, open reduction fixation of fractures, osteotomies, arthroplasties. 15–65 years old. Sex (f/m): 25/38 | Microporous tape directly over the scar for 6 months (EG) or standard care. | POSAS Scar types (normal, hypertrophic, or atrophic). Assessments at 6 weeks, 3 months, and 6 months. | No significant differences between groups at the baseline. At 6 months, the scar height and width were significantly better in EG than CG (p < 0.0001 each), and scar types were significantly better in EG than CG (p = < 0.0001). | 8 |
Jensen et al., 2018 [29] | Randomized, double-blinded, within-subject, placebo-controlled, prospective trial. To determinate the effect of anti-CTFG (EXC001) on the severity of surgical scars. | n = 23 Mammoplasty. Bilateral, symmetric hypertrophic scars of the breast. 28–55 years old. Sex (f/m): 23/0 | EXC001 (EG) or placebo (CG) injected intradermally at post-surgery weeks 2, 5, 8, and 11 | POSAS Assessment at 12 and 24 weeks. | At 24 weeks, EG reduced scar severity significantly compared to CG, by physician (vascularity p < 0.001; pigmentation p < 0.001; thickness p = 0.001; relief p < 0.001; Pliability p = 0.005; surface area p < 0.001; overall opinion p < 0.001) and subjects (pigmentation p = 0.01; stiffness p = 0.003; thickness p = 0.005; surface area p = 0.032 and overall opinion p = 0.003) | 11 |
Karmisholt et al., 2018 [30] | Randomized split-wound, prospective trial. To assess scar formation clinically after three nonablative fractional laser (NAFL) exposures, targeting the inflammation, proliferation, and remodeling wound healing phases in patients vs. untreated controls. | n = 32 Patients undergoing surgical excision. >18 years old Sex (f/m): 15/17 | 1540-nm NAFL (3 exposures: before surgery, at suture removal and 6 weeks after surgery) (EG) or no laser treatment on each side of the scar (CG). | POSAS VSS Assessment at 3 months | 30 patients completed follow-up. At 3 months, EG improved scores compared with the control in POSAS, vascularity, relief, pliability, surface area, and overall opinion (p < 0.001; p = 0.005; p = 0.023; p = 0.037; p = 0.016; p = 0.003), but pigmentation and thickness did not (p = 0.13 each). The greater improvements were located in thorax area (p < 0.001). Patients older and younger than 50 years answered similarly (p = 0.015; p = 0.008) | 9 |
Kong et al., 2020 [31] | Randomized, prospective, controlled trial. To present the experience of adopting tissue adhesive as adjunct to standard wound closure in total hip arthroplasty and evaluate its role and cost performance. | n = 30 Patients with bilateral total hip arthroplasty. 18–60 years old. Sex (f/m): 13/17 | Standard wound closure (GC) or additional tissue adhesive (EG). | PSAS HWES VSS Assessment at 1 month | PSAS showed that, from the view of patients, hips with tissue adhesive were significantly better than sutured hips (p = 0.004). Most patients preferred the tissue adhesive. From view of evaluators, there were not significant differences between groups in HWES or VSS. | 9 |
Lin et al., 2023 [32] | Randomized, prospective, single blinded, split-scar trial. To compare surgical scars treated with fractional carbon dioxide (CO2) laser performed on Day 0 and Day 14. | n = 30 Patients of skin cancer excision on limbs. 34–82 years old Sex (f/m): 13/17 | 2 passes of CO2 laser before the cutaneous suture (day 0) or when sutures were removed (day 14) on each side. | MSS Analytical assessment (biopsy) Assessment at 6 months | 26 subjects completed follow-up. There were no differences between groups for patients (p = 0.058) or physicians (p = 0.028). Fractal dimensions and lacunarity were similar (p = 0.80; p = 0.44). | 8 |
Musham et al., 2023 [33] | Randomized, prospective, controlled, single-blind trial. To compare the skin closure time, postoperative pain, and the scar outcome between tissue adhesive and sub-cuticular sutures in thyroid surgery. | n = 124 Patients of thyroidectomy. 30–55 years old Sex (f/m): 96/28 | Subcuticular suture (CG) or tissue adhesive (EG) | VAS MSS Assessment at post operative, 1, and 3 months. | VAS showed better post operative results in EG (p < 0.01). However, there were not significant differences between groups in MSS at 1 and 3 months. | 9 |
Pangkanon et al., 2021 [34] | Randomized, assessor-blind, prospective controlled trial. To compare the efficacy of silicone gel containing onion extract and aloe vera (SGOA) to silicone gel sheets (SGS) to prevent postoperative hypertrophic scars and keloids. | n = 40 Patients underwent surgery. 18–60 years old Sex (f/m): 36/4 | SGOA twice a day or SGS wound 24 h/day. | POSAS Mexameter Cutometer Assessments at 1, 2, and 3 months. | No differences between groups in number of hypertrophic scars (p = 0.465), melanin (p = 0.571), erythema (p = 0.863), and POSAS by physicians and patients. SGOA group had significantly greater pliability (p = 0.009). | 9 |
Phillips et al., 2018 [35] | Randomized, double blind, prospective controlled trial. To assess the effects of botulinum toxin type A on scar formation after thyroid surgery | n = 40 Patients of total thyroidectomy, hemithyroidectomy, or parathyroidectomy. Sex (f/m): 36/4 | Botulinum toxin A (EG) or saline solution (CG) on each half of the scar. | POSAS VSS Preoperative evaluation. Assessments at 1, 6, and 12 months. | 23 patients completed the last follow-up. There were not significant differences between groups at 1, 6, and 12 months. However, at 6 months, better results were found in EG compared to CG in patients with poor cicatrization history in POSAS total score (p = 0.012), overall (p = 0.010), and VSS (p = 0.021) | 8 |
Ramos et al., 2019 [36] | Non-randomized, double-blinded split-scar prospective trial. To evaluate the influence of photobiomodulation on the post abdominoplasty healing process. | n = 17 Patients of abdominoplasty 18–55 years old Sex (f/m): 17/0 | Right side of scars: 10 sessions of photobiomodulation (experimental side). Left side of scars: any treatment (used as control). | POSAS VSS Assessments at 1, 6, and 12 months. | The treated side of scars was significantly better after 1 and 6 months on VSS (p = 0.0065). The scores of POSAS were better on treated side for observers (p = 0.0034) and patients (p = 0.0047). | 9 |
Safra et al., 2019 [37] | Randomized, controlled, single blinded, split-scar, prospective trial. To study the safety and efficacy of a combination of pulsed dye laser (PDL) and fractional ablative CO2 laser (FACL) for attenuation of post-lumpectomy scarring. | n = 18 Patients of lumpectomy. >18 years old Sex (f/m): 18/0 | Treated side received 3 sessions at 1-month intervals of PDL and FACL 6 weeks after suture removal. The other half of scars did not receive any treatment | POSAS Assessment at 6 months. | The improvements in scar parameters were significantly greater in treated side (overall, pigmentation, and relief p < 0.001; vascularity and pliability p = 0.001; thickness p = 0.002). | 8 |
Surakunprapha et al., 2020 [38] | Randomized, controlled, double-blind, prospective trial. To determine whether adding herbal extracts to the gel would augment the healing effect. | n = 46 Patients of sternotomy 32–61 years old. Sex (f/m): 19/27 | EG: topical silicone gel plus herbal extract gel (Allium cepa, Centella Asiatica, Aloe vera and Paper Mulberry). CG: topical silicone gel | POSAS Assessments at 6 months | At 6 months, EG had significantly greater scores than baseline: vascularity (p = 0.013), pigmentation (p = 0.000), overall (p = 0.018). CG also had improvements in pigmentation (p = 0.000) and vascularity (p = 0.046). | 9 |
Suwannaphisit et al., 2021 [39] | Randomized, prospective controlled trial. To compare the Donati suture technique and running subcuticular technique in terms of surgical scar, pain, and functional outcome. | n = 142 Patients of open carpal tunel release. 48–70 years old. Sex (f/m): 120/18 | Donati or running subcuticular technique. | POSAS Pain (verbal numerical rating score) Assessments at 2, 6, and 12 weeks | At 2 weeks, POSAS showed that subcuticular running technique had lower scores than Donati by the patients (p < 0.05) but not by physicians (p = 0.15). At 6 and 12 weeks, there was no difference between groups in any parameter. | 9 |
Timmermans et al., 2022 [40] | Randomized, prospective, within- subject controlled trial. To establish if incisional negative pressure wound results in improved scar outcomes in comparison to the standard of care. | n = 85 Transgender men undergoing gender-affirming mastectomies. 18–63 years old Sex (f/m): 0/85 | Incisional negative pressure wound (EG) or standard care (CG) on each side. | Cutometer. POSAS Assessments at 1, 3, and 12 months. | 80 patients completed follow-up. At 12 months, there were not significant differences between groups for Cutometer subdomains (p > 0.05). Significant improvements were found in EG compared to CG at 3 months in vascularity, POSAS total score, and overall cosmesis (p = 0.022; p = 0.003; p = 0.004), but these differences were not found at 12 months. By patients, at 1 and 3 months, thickness was better in EG (p = 0.027; p = 0.042), and at 12 months color, pliability, thickness, total score, and overall opinion were better in EG (p = 0.003; p < 0.001; p = 0.003; p = 0.039; p = 0.008). | 9 |
Zhang et al., 2021 [41] | Randomized, single blind, prospective controlled trial. To determine whether the application of a tension offloading device preoperatively would result in superior attenuation of scar genesis in comparison to traditional methods. | n = 12 Patients with a history of hypertrophic scar formation, who underwent surgical excision of benign cutaneous lesions located over buttocks and truncal region. 11–33 years old Sex (f/m): 8/4 | Application of device before (2 weeks) and after surgery (for 3 months, starting from the suture removal) (EG1); application after surgery (for 3 months) (EG2); or no tension offloading (CG) | Skin elasticity coefficient Assessment Before surgery POSAS Assessment at 6 months | The median skin elasticity coefficient was 27.5% in the pre-op group in comparison to 15% in both the post-op group and the control group (p = 0.0286). EG1 and EG2 did not show significant differences. There were differences compared to CG in terms of width and color. Overall Score was significantly better between 3 groups by patients but only between offloaded groups and CG by physicians. | 8 |
Zoumalan et al., 2019 [42] | Randomized, double-blinded, multicenter, prospective trial. To compare the efficacy and safety of a scar cream consisting on highly selective human growth factors (SKN2017B) and hyaluronic acid within a silicone matrix. | n = 45 (49 bilateral and 12 unilateral scars) Surgical patients with unilateral or bilateral scars on their face. >18 years old. Sex (f/m): 43/2 | SKN2017B or silicone cream twice for 3 months. Unilateral scars were randomly assigned in split-scar and bilateral scars were assigned by sides. | VSS Assessment at 12 weeks. (Independent Assessment) | Investigators rated 74% improvements in SKN2017B group and 54% in silicone group (p < 0.0001), patients rated 85% and 51% improvements respectively (p < 0.001). Independent reviewers rated 87% and 1% (p < 0.0001). | 8 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bueno, A.; Nevado-Sanchez, E.; Pardo-Hernández, R.; de la Fuente-Anuncibay, R.; González-Bernal, J.J. Treatment and Improvement of Healing after Surgical Intervention. Healthcare 2023, 11, 2213. https://doi.org/10.3390/healthcare11152213
Bueno A, Nevado-Sanchez E, Pardo-Hernández R, de la Fuente-Anuncibay R, González-Bernal JJ. Treatment and Improvement of Healing after Surgical Intervention. Healthcare. 2023; 11(15):2213. https://doi.org/10.3390/healthcare11152213
Chicago/Turabian StyleBueno, Andrea, Endika Nevado-Sanchez, Rocío Pardo-Hernández, Raquel de la Fuente-Anuncibay, and Jerónimo J. González-Bernal. 2023. "Treatment and Improvement of Healing after Surgical Intervention" Healthcare 11, no. 15: 2213. https://doi.org/10.3390/healthcare11152213